Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates?

Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals?

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation...

PSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Trading in Biogen was halted on November 6, 2020, in advance of...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biogen Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether Biogen Inc. (NASDAQ: BIIB) ("Biogen" or the "Company") complied with federal securities laws. Trading in Biogen was halted on November 6, 2020, in advance of the Company's meeting with the FDA. On the same day, Bloomberg reported in an article titled "Biogen Alzheimer's Drug Fails to Gain FDA Panel's Backing," that "the outside experts voted 8 to...

SHAREHOLDER ALERT: Investigation of Biogen Announced by Holzer & Holzer, LLC

Aurinia Pharmaceuticals

Heron Therapeutics

Cassava Sciences Inc

This biotech titan should be a top player on the merger and acquisition scene next year.

Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy

The odds appear to be heavily against this Berkshire investment paying off.

Why Warren Buffett's Riskiest Bet in Years Is on the Brink of Bombing

Biogen has an impressive portfolio of assets, with recent FDA announcements from Friday casting a shadow. The company is obviously undervalued if Aducanumab is approved, but the question is what about if it isn't.

Biogen Hits A Wall, What's Next?

New York, New York--(Newsfile Corp. - November 9, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) resulting from allegations that Biogen may have issued materially misleading business information to the investing public.On November 6, 2020, Biogen trading was halted before the Company's meeting with the U.S. Food and Drug Administration ("FDA").Later that day, Bloomberg published an...

Rosen, A Global and Leading Law Firm, Announces Investigation of Securities Claims Against Biogen Inc.; Encourages Investors with Losses in Excess of $500K to Contact Firm - BIIB

Biogen Inc (NASDAQ: BIIB) shares are retreating sharply after an Adcom committee recommended against approval of its investigational Alzheimer's drug aducanumab. Despite the setback, an analyst at SVB Leerink said aducanumab could still successfully clear the final FDA hurdle.

Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab

The world may have been fighting COVID-19 in 2020, but there has been a multi-decade fight against Alzheimer's disease.

Mixed Views So Far on FDA Approval of Biogen's Aducanumab for Alzheimer's

Biogen stock crashed Monday after a Food and Drug Administration panel voted against recommending its controversial Alzheimer's treatment for approval. Shares were down more than 30% early.

Biogen Stock Crashes After FDA Panel Rejects Alzheimer's Treatment

The biotech's high-profile Alzheimer's disease drug candidate appears to be headed for a rejection.

Why Biogen Stock Is Tanking Today

Biogen experienced a quick reversal in fortunes on Monday, with its stock plummeting after an FDA Advisory Committee said it was unconvinced that data from its Alzheimer's therapy was enough to demonstrate efficacy. Friday's FDA AdCom votes came two days after Biogen soared 47% after FDA scientists said data from its aducanumab trials was "exceptionally persuasive."

Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee

Biogen Inc's shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

Biogen plunges 30% after FDA panel votes against Alzheimer's drug

If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel

Wall Street analysts suggest that Biogen Inc (NASDAQ: BIIB) stock is about to see a significant selloff and could witness volatility until the Food and Drugs Administration (FDA) review process comes to a close in March 2021, Bloomberg reports. The analyst forecasts were based on expectations that the company's developmental treatment for Alzheimer's disease, Aducanumab, would not be approved by the FDA.

Analysts Predict Volatility In Biogen Shares Until March 2021

CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for Study 301 (ENGAGE), provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer's disease?”. The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer's disease?”, and 5 yes, 0 no and 6 uncertain on the question, “Has the Applicant presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer's disease pathophysiology?”. Finally, the Advisory Committee voted 0 yes, 10 no and 1 uncertain on the question, “In light of the understanding provided by the exploratory analyses of Study 301 and Study 302, along with the results of Study 103 and evidence of a pharmacodynamic effect on Alzheimer's disease pathophysiology, it is reasonable to consider Study 302 as primary evidence of effectiveness of aducanumab for the treatment of Alzheimer's disease?”

Update on FDA Advisory Committee's Meeting on Aducanumab in Alzheimer's Disease

NEW YORK, Nov. 6, 2020 /PRNewswire/ -- An independent FDA advisory committee today signaled in several votes that it does not believe the clinical study data for Biogen's aducanumab supports the drug's approval for patients with early stage Alzheimer's disease. "Although today's...

Alzheimer's Drug Discovery Foundation Statement on Today's FDA Independent Panel Vote on Biogen's Aducanumab

The committee of outside experts saw right through the FDA's cheerleading.

FDA Committee Votes Strongly Against Biogen's Alzheimer's Disease Drug

The future of an experimental Alzheimer's drug was thrown back into substantial doubt on Friday, as an influential expert panel concluded the treatment had not shown enough evidence of effectiveness.  The committee's negative recommendations came in stark contrast to the FDA's own position. In briefing documents released Wednesday, the regulatory agency stated there was "substantial evidence of effectiveness to support approval."

An influential group of health experts rejects Biogen's experimental Alzheimer's drug, casting substantial doubt over the drug's chances of approval (BIIB)

Biogen Inc (NASDAQ: BIIB) failed to win the backing of the FDA panel which reviewed the BLA for its controversial Alzheimer's drug aducanumab, an antibody which targets amyloid-beta. What Happened: FDA's Peripheral and Central Nervous System Drugs Advisory Committee met Friday to discuss the BLA voted with eight 'no' votes and 'one' yes vote on the question of whether the Phase 3 Study 302, viewed independently and without regard for the failed Study 301, provided strong evidence supporting the effectiveness of aducanumab for the treatment of Alzheimer's disease.

Biogen's Aducanumab Fails To Win FDA Panel Backing

If fully approved, it would be the first drug to slow cognitive decline in people living with the disease and the first new treatment for Alzheimer's in nearly 20 years.

Biogen hits snag after Alzheimer's drug fails to win support from FDA panel

Biogen Inc. BIIB appears to have suffered a setback on Friday at the hands of a Food and Drug Administration advisory panel over recommendation to approve its experimental Alzheimer's disease treatment. On Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 8 to 1 against recommending approval of Biogen's treatment aducanumab, while two members cast “undecided” votes, according to reports and multiple tweets Friday.

Biogen Alzheimer's drug appears to have setback as FDA advisers recommend not to approve

The stock price of Biogen Inc (NASDAQ: BIIB) has received a price target increase from $342 to $402 by SVB Leerink. These are the details.

BIIB Stock: $402 Price Target By SVB Leerink

Biogen stock was halted early Friday ahead of a Food and Drug Administration advisory committee meeting to discuss the fate of its controversial Alzheimer's treatment, aducanumab. The post Biogen Stock Halted As FDA Panel Prepares To Discuss Alzheimer's Drug appeared first on Investor's Business Daily.

News for Biogen Stock (BIIB)